2. Induced Disease Models Products Others
  3. Cardiovascular System Disease Models Biochemical Assay Reagents
  4. Hyperlipidemia Models
  5. Tyloxapol

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol is used to induce hyperlipidemia in animals.

For research use only. We do not sell to patients.

CAS No. : 25301-02-4

Size Price Stock Quantity
500 mg In-stock
1 g In-stock
5 g In-stock
10 g In-stock
25 g In-stock
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Tyloxapol Related Antibodies

Top Publications Citing Use of Products

    Tyloxapol purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 May 24.  [Abstract]

    Plasma triglyceride levels in mice in the vector control group and the Retemeritol treatment group after gavage administration of olive oil and intraperitoneal injection of Tyloxapol (10% in saline, 500 mg/kg, ip, single dose) (lipid absorption model).

    Tyloxapol purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 May 24.  [Abstract]

    Plasma triglyceride levels after intraperitoneal injection of Tyloxapol (10% in saline, 500 mg/kg, ip, single dose) (very low-density lipoprotein secretion model).

    Tyloxapol purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 May 24.  [Abstract]

    Plasma TG after gavage with olive oil and intraperitoneal injection of Tyloxapol (10% in saline, 500 mg/kg, ip, single dose) (lipid absorption) in vehicle, CA, Resmetirom and CA plus Resmetirom-treated normal mice.

    Tyloxapol purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 May 24.  [Abstract]

    Plasma TG after gavage with olive oil and intraperitoneal injection of Tyloxapol (10% in saline, 500 mg/kg, ip, single dose) (lipid absorption) in vehicle, CA, resmetirom and CA plus Resmetirom-treated CDAHFD-fed mice.

    Tyloxapol purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 May 7;25(10):5086.

    L02 cells were transfected with GSTA1 or control plasmids for 36 h and further treated with or without bicyclol for 12 h. Intracellular TG levels were analyzed after induction by OA containing Tyloxapol (200 µM), a lipoprotein lipase inhibitor that can inhibit the breakdown of triglycerides by binding to lipase. Overexpression of GSTA1 or treatment with bicyclol significantly decreased the rate of TG synthesis compared to the control.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol is used to induce hyperlipidemia in animals[1][2].

    In Vitro

    Tyloxapol (100 μg/mL) triggers the detachment of HEK293 cells[2].
    Tyloxapol induces nuclear fragmentation and the appearance of apoptotic nuclei[2].
    Tyloxapol increases the risk of pulmonary haemorrhage, causes cytotoxicity in epithelial and red blood cells, and induces lysis of human Jurkat T-lymphoblasts[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Tyloxapol Related Antibodies
    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    Tyloxapol (Triton WR1339, 50 mg/kg) causes significant decreases in the activities of the AChE and MAO enzymes in rat plasma and brain[1].
    Tyloxapol leads to significant reduction in the plasma urea, creatinine, and bilirubin[1].

    Tyloxapol can be used in animal modeling to construct models of Hyperlipidemia[1][2][3].
    Induction of hyperlipemia.
    Background
    Hyperlipidemia is characterized by high levels of plasma triglycerides and LDL-cholesterol, accompanied by reduced HDL-cholesterol levels. Tyloxapol increases plasma cholesterol (Chol) levels by promoting hepatic Chol synthesis, particularly via increased 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity. In addition, Tyloxapol directly disturbs lipolytic enzymes responsible for hydrolysis of plasma lipids, such as lipoprotein lipases, thus blocking the uptake of lipids from circulation to extra-hepatic tissues, resulting in increased blood lipid concentration.
    Specific Modeling Methods
    Rats: Wistar• male• weighing 300-360 g[1].
    Administration: 400 mg/kg• i.p.• a single dose for 24 h[1].
    Rats: Wistar-Imamichi• male• weighing 230-270 g[2].
    Administration: 400 mg/kg• i.v. through a tail vein• a single dose for 24 h[2].
    Rats: Wistar• male• 11-12 weeks of age• weighing 180-200 g[3].
    Administration: 50 mg/kg• i.p.• every other day for 28 days[3].
    Note
    (1) Before administration, animals were housed at 22±2°C, under a 12-h/12-h light/dark cycle, with 60% relative humidity, and received water and food ad libitum[1][2].
    (2) Tyloxapol was dissolved in phosphate buffer solution (PBS, pH 7.4). Twenty-four hours after administration, blood, liver, kidney, and forebrain tissues samples were collected for the comet assay. Bone marrow samples of from femurs were collected to perform the micronucleus assay[1].
    (3) At the end of the 28th day of the experimental period, all animals of each group were anesthetized with ether and sacrificed. Blood samples were collected from anesthetized rats in test tubes containing heparin as an anticoagulant and placed immediately on ice[3].
    Modeling Indicators
    Molecular changes: Tyloxapol increased the levels of Chol, triglycerides (TG), glucose, albumin, creatinine and urea. Tyloxapol had high DNA damage in peripheral blood, liver and kidney[1][2].
    Histological analysis: Hepatocytic damage was manifested by obvious fat vacuolation, the hepatic veins were dilated and congested with blood. Furthermore, the hepatocytic cells were necrosed and abnormal localization and infiltration of hepatocytic nuclei were showed[3].
    Opposite Product(s): Simvastatin (HY-17502); ML-236B (HY-17408); Soybean oil (HY-108750)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Twenty-one adult male Wistar rats, aged 11–12 weeks weighing 180-200 g[1].
    Dosage: 50 mg/kg.
    Administration: Injected intraperitoneally, BW, every other day.
    Result: Caused a significant (P < 0.05) elevation in the levels of TBARS combined with an inhibition of the antioxidant enzymes (GPx, GST, CAT, SOD) in rat plasma, liver, and brain.
    Induced DNA fragmentation and inhibited the activities of acetylcholinesterase and mono aminoxidase in the brain.
    Clinical Trial
    Molecular Weight

    261.38 (monomer)

    Formula

    (C15H21O(C2H4O)m)n
    CAS No.
    Appearance

    Liquid (Density: 1.1 g/cm3)

    Color

    Colorless to light yellow

    SMILES

    [H]OCCOC1=C(CC)C=C(C(CC(C)(C)C)(C)C)C=C1C.[6].[=].[<].[5].[8].[n].[m].[_].[=].[m].[n]
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    H2O : 120 mg/mL (Need ultrasonic)

    Ethanol : 100 mg/mL (Need ultrasonic)

    DMSO : ≥ 38 mg/mL

    *"≥" means soluble, but saturation unknown.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL; Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% EtOH    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL; Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL; Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    SDS (393 KB)

    COA (251 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Tyloxapol Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Tyloxapol25301-02-4Biochemical Assay ReagentsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tyloxapol
    Cat. No.:
    HY-B1068
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.